Recursion and Genentech said they will co-develop a neuroscience small-molecule program after Genentech accepted the first validated target option from an AI-generated map. The milestone includes a $3 million payment to Recursion and expands a collaboration structure where each program can generate up to $300 million in development, commercialization, and sales-related milestones plus tiered royalties. Recursion emphasized that it took about 15 months from initiation to deliver the validation package for the first target, and noted the program sits within neuroscience and undisclosed gastrointestinal oncology areas. The move signals the practical transition of AI target discovery into early discovery-to-co-development processes.